Inlyta and Nephritis - interstitial - a phase IV clinical study of FDA data

Summary:

Nephritis - interstitial is reported as a side effect among people who take Inlyta (axitinib), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Keytruda, and have Renal cell carcinoma.

The phase IV clinical study analyzes which people have Nephritis - interstitial when taking Inlyta. It is created by eHealthMe based on reports of 17,657 people who have side effects when taking Inlyta from the FDA, and is updated regularly.

What is Inlyta?

Inlyta has active ingredients of axitinib. eHealthMe is studying from 17,662 Inlyta users. Check the latest studies of Inlyta.

What is Nephritis - interstitial?

Nephritis - interstitial (a kidney condition characterized by swelling in between the kidney tubules) is found to be associated with 1,486 drugs and 1,568 conditions by eHealthMe. Check the latest studies of Nephritis - interstitial.

On Jul, 24, 2026

17,657 people reported to have side effects when taking Inlyta.
Among them, 16 people (0.09%) have Nephritis - interstitial.

Could Inlyta cause Nephritis - interstitial?

Among these 16 people:

How long have people been on Inlyta when they have Nephritis - interstitial? *

What is the gender of people who have Nephritis - interstitial when taking Inlyta? *

female: 26.67 %
male: 73.33 %

What is the age of people who have Nephritis - interstitial when taking Inlyta? *

What are other drugs people take besides Inlyta? *

What are other side effects people have besides Nephritis - interstitial? *

Interstitial Lung Disease: 3 people, 18.75%
Diarrhea: 2 people, 12.50%
Fatigue (feeling of tiredness): 2 people, 12.50%
Haematuria (presence of blood in urine): 2 people, 12.50%
Hepatitis (inflammation of the liver): 2 people, 12.50%
High Blood Pressure: 2 people, 12.50%
Hormone Level Abnormal: 2 people, 12.50%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 12.50%
Disturbance In Attention: 2 people, 12.50%
Kidney Infection: 2 people, 12.50%

What are the existing conditions these people have? *

Renal Cell Carcinoma (a kidney cancer): 9 people, 56.25%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 3 people, 18.75%
Urinary Tract Infection: 2 people, 12.50%
Joint Pain: 2 people, 12.50%
Gastrointestinal Stromal Tumor: 2 people, 12.50%
Thrombosis (formation of a blood clot inside a blood vessel): 1 person, 6.25%
Renal Cancer Stage Iv (the tumour has spread to areas beyond gerota's fascia and extends into the adrenal gland on the same side of the body as the tumour, possibly to lymph nodes, but not to other parts of the body): 1 person, 6.25%
High Blood Pressure: 1 person, 6.25%
Anaemia (lack of blood): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Inlyta and have Nephritis - interstitial?

- Check whether Nephritis - interstitial is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Inlyta:

Inlyta (17,662 reports)

Browse all side effects of Inlyta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nephritis - interstitial:

Nephritis - interstitial (1,486 drugs)

Browse all the conditions that are associated with Nephritis - interstitial:

Nephritis - interstitial (1,568 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on axitinib (the active ingredients of Inlyta) and Inlyta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.